Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(3):347-351 | DOI: 10.5507/bp.2015.041

Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Zdenek Frysaka, Jan Schovaneka, Maurizio Iacoboneb, David Karaseka
a Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, I.P.Pavlova 6 - 779 00, - Olomouc, Czech Republic
b Minimally Invasive Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy, Via Giustiniani 2 - 35128 - Padova, Italy

Background and Aims: Interest in growth hormone (GH) is inextricably linked to the need for in depth understanding of the somatomedins (insulin-like growth factors) which are polypeptides structurally similar to insulin and with broad physiological activity. To date, the most commonly known is Insulin-Like Growth Factor I (IGF-I). Despite considerable current knowledge of IGF-I, however, its bioactivity is incompletely understood. Measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The development of recombinant IGF-I, has allowed its use in such cases. Clinical practice, however, shows that few young/adult patients will benefit from treatment with the rIGF-I, mecasermin, given the number of adverse effects found. This review focuses on current knowledge mainly related to IGF-I and the use of its recombinant form (rIGF-I) in clinical practice. Several functions of IGI-II have been elucidated but their clinical significance is unclear.

Keywords: Somatomedins, Insulin-Like Growth Factor I, II, IGF-I receptor, Human Growth Hormone, Recombinant Human Growth Hormone, Acid Labile Subunit, IGF Binding Proteins, Mecasermin, Insulin Receptor Isoform A, acromegaly, growth hormone deficiency

Received: April 28, 2015; Accepted: July 28, 2015; Prepublished online: September 2, 2015; Published: September 30, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Frysak, Z., Schovanek, J., Iacobone, M., & Karasek, D. (2015). Insulin-like Growth Factors in a clinical setting: Review of IGF-I. Biomedical papers, 159(3), 347-351. doi: 10.5507/bp.2015.041
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Salmon WD, Jr., Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49(6):825-36.
    2. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253(8):2769-76. Go to original source...
    3. Han VK, D'Ercole AJ, Lund PK. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987;236(4798):193-7. Go to original source... Go to PubMed...
    4. Hoppener JW, de Pagter-Holthuizen P, Geurts van Kessel AH, Jansen M, Kittur SD, Antonarakis SE, Lips CJ, Sussenbach JS. The human gene encoding insulin-like growth factor I is located on chromosome 12. Hum Genet 1985;69(2):157-60. Go to original source... Go to PubMed...
    5. Brissenden JE, Ullrich A, Francke U. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 1984;310(5980):781-4. Go to original source... Go to PubMed...
    6. Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association of Klotho polymorphisms with healthy aging: a systematic review and meta-analysis. Rejuvenation Res 2014;17(2):212-6. Go to original source... Go to PubMed...
    7. Batey L, Moon JE, Yu Y, Wu B, Hirschhorn JN, Shen Y, Dauber A. A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency. J Clin Endocrinol Metab 2014;99(1):E153-9. Go to original source... Go to PubMed...
    8. Varela-Nieto I, Murillo-Cuesta S, Rodriguez-de la Rosa L, Lassatetta L, Contreras J. IGF-I deficiency and hearing loss: molecular clues and clinical implications. Pediatr Endocrinol Rev 2013;10(4):460-72. Go to PubMed...
    9. Ziv E, Hu D. Genetic variation in insulin/IGF-1 signaling pathways and longevity. Ageing Res Rev 2011;10(2):201-4. Go to original source... Go to PubMed...
    10. Cox OT, O'Shea S, Tresse E, Bustamante-Garrido M, Kiran-Deevi R, O'Connor R. IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance. Front Endocrinol (Lausanne) 2015;6:106. Go to original source... Go to PubMed...
    11. Janssen JA, Varewijck AJ. IGF-IR Targeted Therapy: Past, Present and Future. Front Endocrinol (Lausanne) 2014;5:224. Go to original source... Go to PubMed...
    12. Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab 2014;25(3):128-37. Go to original source... Go to PubMed...
    13. Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association between genetic variations in the insulin/insulin-like growth factor (Igf-1) signaling pathway and longevity: a systematic review and meta-analysis. Curr Vasc Pharmacol 2014;12(5):674-81. Go to original source... Go to PubMed...
    14. Walenkamp MJ, Losekoot M, Wit JM. Molecular IGF-1 and IGF-1 receptor defects: from genetics to clinical management. Endocr Dev 2013;24:128-37. Go to original source... Go to PubMed...
    15. Succurro E, Andreozzi F, Marini MA, Lauro R, Hribal ML, Perticone F, Sesti G. Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutr Metab Cardiovasc Dis 2009;19(10):713-9. Go to original source... Go to PubMed...
    16. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002;359(9319):1740-5. Go to original source... Go to PubMed...
    17. Sandhu MS, Gibson JM, Heald AH, Dunger DB, Wareham NJ. Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev 2004;13(1):166-70. Go to PubMed...
    18. van Bunderen CC, van Nieuwpoort IC, van Schoor NM, Deeg DJ, Lips P, Drent ML. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 2010;95(10):4616-24. Go to original source... Go to PubMed...
    19. Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol 2014;2(7):581-92. Go to original source... Go to PubMed...
    20. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012;41(2):425-43, vii-viii. Go to original source... Go to PubMed...
    21. Eddy KT, Lawson EA, Meade C, Meenaghan E, Horton SE, Misra M, Klibanski A, Miller KK. Appetite regulatory hormones in women with anorexia nervosa: binge-eating/purging versus restricting type. J Clin Psychiatry 2015;76(1):19-24. Go to original source... Go to PubMed...
    22. Misra M, Miller KK, Herzog DB, Ramaswamy K, Aggarwal A, Almazan C, Neubauer G, Breu J, Klibanski A. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J Clin Endocrinol Metab 2004;89(4):1605-12. Go to original source... Go to PubMed...
    23. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121(6):753-8. Go to original source... Go to PubMed...
    24. Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA, Froesch ER. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 1995;95(1):179-86. Go to original source... Go to PubMed...
    25. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170(1):63-70. Go to original source... Go to PubMed...
    26. Domene HM, Hwa V, Jasper HG, Rosenfeld RG. Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab 2011;25(1):101-13. Go to original source... Go to PubMed...
    27. Ramadhin C, Pillay B, Olaniran AO. Cell-based assays for IGF-I bioactivity measurement: overview, limitations and current trends. Growth Factors 2014;32(3-4):130-8. Go to original source... Go to PubMed...
    28. Daughaday WH, Parker KA, Borowsky S, Trivedi B, Kapadia M. Measurement of somatomedin-related peptides in fetal, neonatal, and maternal rat serum by insulin-like growth factor (IGF) I radioimmunoassay, IGF-II radioreceptor assay (RRA), and multiplication-stimulating activity RRA after acid-ethanol extraction. Endocrinology 1982;110(2):575-81. Go to original source... Go to PubMed...
    29. Khosravi MJ, Diamandi A, Mistry J, Lee PD. Noncompetitive ELISA for human serum insulin-like growth factor-I. Clin Chem 1996;42(8 Pt 1):1147-54. Go to original source...
    30. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17. Go to original source... Go to PubMed...
    31. Bolanowski M, Ruchala M, Zgliczynski W, Kos-Kudla B, Baldys-Waligorska A, Zielinski G, Bednarczuk T, Hubalewska-Dydejczyk A, Kaminski G, Marek B, Daroszewski J, Wasko R, Lewinski A. Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol 2014;65(4):326-31. Go to original source... Go to PubMed...
    32. Cap J, Cerman J, Nemecek S, Marekova M, Hana V, Frysak Z. The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 2003;10(4):444-8. Go to original source... Go to PubMed...
    33. Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, Maisonobe P, Clermont A. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014;99(4):1282-90. Go to original source... Go to PubMed...
    34. Lebl J, Zapletalova J. Léčba růstovým hormonem v pediatrii. Historie a současnost. Klin Farmakol 2011;25(1):18-23.
    35. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157(6):695-700. Go to original source... Go to PubMed...
    36. Newman CB, Carmichael JD, Kleinberg DL. Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary 2015;18(3):297-305. Go to original source... Go to PubMed...
    37. Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, Nelson CA, 3rd, Vogel-Farley V, DeGregorio G, Holm IA, Khatwa U, Kapur K, Alexander ME, Finnegan DM, Cantwell NG, Walco AC, Rappaport L, Gregas M, Fichorova RN, Shannon MW, Sur M, Kaufmann WE. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A 2014;111(12):4596-601. Go to original source... Go to PubMed...
    38. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004;89(3):1031-44. Go to original source... Go to PubMed...
    39. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism? Isr J Med Sci 1966;2(2):152-5.
    40. Kronenberg HM, Melmed S, Larsen PR, Polonsky KS. CHAPTER 1 - Principles of Endocrinology. In: Kronenberg SMSPRLM, editor. Williams Textbook of Endocrinology (Twelfth Edition). Philadelphia: Content Repository Only!; 2011. p. 3-12. Go to original source...
    41. Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000;85(4):1407-11. Go to original source... Go to PubMed...
    42. Ros P, Colino-Alcol E, Grasso V, Barbetti F, Argente J. [Severe type A insulin resistance syndrome due to a mutation in the insulin receptor gene]. An Pediatr (Barc) 2015;82(1):e30-4. Go to original source... Go to PubMed...
    43. Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol 2013;9(6):346-56. Go to original source... Go to PubMed...
    44. Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 2012;97(12):4769-79. Go to original source... Go to PubMed...
    45. Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab 2014;99(1):338-43. Go to original source... Go to PubMed...
    46. Yarwood GD, Ross RJ, Medbak S, Coakley J, Hinds CJ. Administration of human recombinant insulin-like growth factor-I in critically ill patients. Crit Care Med 1997;25(8):1352-61. Go to original source... Go to PubMed...
    47. Hajsadeghi S, Khamseh ME, Gholami S, Kerman SR, Gohardehi G, Moghadam NS, Sabet AS, Moradi M, Mollahoseini R, Najafi M, Keramati MR. IGF-I concentration and changes in critically ill patients. J Res Med Sci 2011;16(2):170-8.
    48. Elijah IE, Branski LK, Finnerty CC, Herndon DN. The GH/IGF-1 system in critical illness. Best Pract Res Clin Endocrinol Metab 2011;25(5):759-67. Go to original source... Go to PubMed...
    49. Teng Chung T, Hinds CJ. Treatment with GH and IGF-1 in critical illness. Crit Care Clin 2006;22(1):29-40, vi. Go to original source... Go to PubMed...
    50. Latrech H, Simon A, Beltrand J, Souberbielle JC, Belmejdoub G, Polak M. Postprandial hyperglycemia corrected by IGF-I (Increlex(R)) in Laron syndrome. Horm Res Paediatr 2012;78(3):193-200. Go to original source... Go to PubMed...
    51. Kemp SF. Mecasermin rinfabate. Drugs Today (Barc) 2007;43(3):149-55. Go to original source... Go to PubMed...
    52. Kemp SF. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options. BioDrugs 2009;23(3):155-63. Go to original source... Go to PubMed...
    53. Kemp SF, Fowlkes JL, Thrailkill KM. Efficacy and safety of mecasermin rinfabate. Expert Opin Biol Ther 2006;6(5):533-8. Go to original source... Go to PubMed...
    54. Fintini D, Brufani C, Cappa M. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag 2009;5(3):553-9. Go to original source...
    55. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM. A critical role for IGF-II in memory consolidation and enhancement. Nature 2011;469(7331):491-7. Go to original source... Go to PubMed...

    Return to the content